Avinger, Inc. announced that it has entered into a Securities Purchase Agreement with new investor, Zylox-Tonbridge Medical Technology Co., Ltd., pursuant to which the Purchaser agreed to purchase the shares of the Company?s common stock, par value $0.001 per share and shares of two new series of the Company?s preferred stock for the aggregate gross proceeds of $15,000,000 on March 4, 2024. The purchaser agreed to purchase in two tranches. Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of Common Stock at a conversion price equal to the Purchase Price, subject to the terms of the Certificate of Designation of Preferences, Rights, and Limitations of the Series F Preferred Stock.
Zylox-Tonbridge Medical Technology Co., Ltd.
Equities
2190
CNE100004JD2
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.4 HKD | +1.17% | -2.99% | -16.40% |
May. 09 | Zylox-Tonbridge Medical Technology Co., Ltd. Announces Retirement of Hongze Liang as an Independent Non-Executive Director | CI |
Mar. 22 | Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.40% | 426M | |
+12.05% | 126B | |
-9.24% | 10.89B | |
+0.29% | 9.02B | |
+36.99% | 5.41B | |
-21.98% | 4.6B | |
+8.02% | 3.44B | |
-10.32% | 2.74B | |
-12.33% | 2.06B | |
-13.53% | 1.96B |
- Stock Market
- Equities
- 2190 Stock
- News Zylox-Tonbridge Medical Technology Co., Ltd.
- Avinger, Inc. announced that it expects to receive $15 million in funding from Zylox-Tonbridge Medical Technology Co., Ltd.